# US 2025/0145686 A1 · Uterine cancer treatments > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2025/0145686 A1 - Document ID: US20250145686A1 - Status: Published application - Kind: A1 - Application number: 19/012,311 - Filed: 2025-01-07 - Published: 2025-05-08 - Earliest claimed: 2016-03-08 - Assignees: Immatics Biotechnologies GmbH - Applicants: Immatics Biotechnologies GmbH - Inventors: Andrea MAHR; Toni WEINSCHENK; Colette SONG; Oliver SCHOOR; Jens FRITSCHE; Harpreet SINGH - Web page: https://patentgrep.com/patent/US20250145686A1 ## CPC - C07K 14/70539: {MHC-molecules, e.g. HLA-molecules} - A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00) - A61K 38/1709: {from mammals} - A61K 39/0011: {Cancer antigens} - A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells - A61K 40/42: Cancer antigens - A61P 35/00: Antineoplastic agents - A61P 35/02: specific for leukemia - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - C07K 7/06: having 5 to 11 amino acids - C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE} - C07K 14/7051: {T-cell receptor (TcR)-CD3 complex} - C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules} - C12N 5/0636: {T lymphocytes} - C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers} - C12Q 1/6881: for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes - G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites} - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells} - C07K 7/00: Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof - C07K 2319/00: Fusion polypeptide - C07K 2319/70: containing domain for protein-protein interaction - C12N 2310/16: Aptamers - C12Q 2600/136: Screening for pharmacological compounds - C12Q 2600/156: Polymorphic or mutational markers - G01N 2333/70539: MHC-molecules, e.g. HLA-molecules - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. ## Claims ### Claim 1 A peptide consisting of the amino acid sequence selected from SEQ ID NO: 2-5, 7, 9-11, and 14-71 in the form of a pharmaceutically acceptable salt. ### Claim 2 (depends on 1) The peptide of claim 1, wherein said peptide has the ability to bind to an MHC class-I molecule, and wherein said peptide, when bound to said MHC, is capable of being recognized by CD8 T cells. ### Claim 3 (depends on 1) The peptide of claim 1, wherein the pharmaceutically acceptable salt is chloride salt. ### Claim 4 (depends on 1) The peptide of claim 1, wherein the pharmaceutically acceptable salt is acetate salt. ### Claim 5 (depends on 1) A composition comprising the peptide of claim 1 and a pharmaceutically acceptable carrier. ### Claim 6 (depends on 5) The composition of claim 5, wherein the peptide is in the form of a chloride salt. ### Claim 7 (depends on 5) The composition of claim 5, wherein the peptide is in the form of an acetate salt. ### Claim 8 (depends on 5) The composition of claim 5, further comprising an adjuvant selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23. ### Claim 9 (depends on 8) The composition of claim 8, wherein the adjuvant is IL-2. ### Claim 10 (depends on 8) The composition of claim 8, wherein the adjuvant is IL-7. ### Claim 11 (depends on 8) The composition of claim 8, wherein the adjuvant is IL-12. ### Claim 12 (depends on 8) The composition of claim 8, wherein the adjuvant is IL-15. ### Claim 13 (depends on 8) The composition of claim 8, wherein the adjuvant is IL-21. ### Claim 14 (depends on 1) The peptide in the form of a pharmaceutically acceptable salt of claim 1, wherein said peptide is produced by solid phase peptide synthesis or produced by a yeast cell or bacterial cell expression system. ### Claim 15 (depends on 1) A composition comprising the peptide of claim 1, wherein the composition is a pharmaceutical composition and comprises water and a buffer. ### Claim 16 A peptide consisting of the amino acid sequence selected from SEQ ID NO: 2-5, 7, 9-11, and 14-71 in the form of a salt. ### Claim 17 A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present on the surface a peptide consisting of the amino acid sequence selected from SEQ ID NO: 2-5, 7, 9-11, and 14-71, wherein the activated T cells bind the peptide in a complex with an MHC class I molecule on the surface of the cancer cells, and wherein the cancer is selected from uterine cancer, acute myelogenous leukemia, breast cancer, bile duct cancer, brain cancer, chronic lymphocytic leukemia, colorectal carcinoma, esophageal cancer, gallbladder cancer, gastric cancer, hepatocellular cancer, Merkel cell carcinoma, melanoma, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer, small cell lung cancer, and urinary bladder cancer. ### Claim 18 (depends on 17) The method of claim 17, wherein the activated T cells are cytotoxic T cells produced by transducing T cells with a T cell receptor (TCR) that binds the peptide in a complex with an MHC class I molecule on the surface of the cancer cells. ### Claim 19 (depends on 17) The method of claim 17, further comprising administering to said patient at least one adjuvant selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides, poly-(I:C), RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23. ### Claim 20 (depends on 19) The method of claim 19, wherein the at least one adjuvant is IL-2.